The tobacco endgame—eradicating a worsening epidemic

A Joint Opinion From the American College of Cardiology, American Heart Association, European Society of Cardiology, and the World Heart Federation

Jeffrey Willett¹, Stephan Achenbach²,³, Fausto J. Pinto⁴,⁵, Athena Poppas⁶,⁷, and Mitchell S.V. Elkind⁸,⁹,¹⁰*

¹American Heart Association, 7272 Greenville Ave, Dallas, TX 75231, USA; ²European Society of Cardiology, The European Heart House, Les Templiers, 2035 route des collées, CS 80179 Biôt, 06903 Sophia Antipolis Cedex, France; ³Department of Cardiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Ulmenweg 18 91054, Erlangen, Germany; ⁴World Heart Federation, Rue de Malatrex 32, 1201 Geneva, Switzerland; ⁵AIDFM Hospital de Santa Maria c/o Luísa Buscardini, Av. Prof. Egas Moniz Piso, 01 1649-028 Lisboa, Portugal; ⁶American College of Cardiology, 2400 N Street NW, Washington, DC 20037; ⁷Brown University, Lifespan Cardiovascular Institute, 2 Dudley St., Ste. 360 Providence, RI 02905-3248, USA; ⁸American Heart Association, 7272 Greenville Ave, Dallas, TX 75231; ⁹Department of Neurology, Columbia University, 710 W 168th St, New York, NY 10032, USA; and ¹⁰Department of Epidemiology, Columbia University, 710 W 168th St, New York, NY 10032, USA

Online publish-ahead-of-print 26 May 2021

Problem

Tobacco use continues to be a primary contributor to the global burden of disease, causing an estimated 12% of deaths worldwide among people ≥30 years of age.¹ Annually, tobacco kills 8 million people around the world, including 1.2 million non-smokers who are exposed to second-hand smoke.² Globally, 21% of adults, >1 billion people, are current smokers, and >80% of the world’s smokers live in low- and middle-income countries. Most adult smokers report wanting to quit, but too many find it challenging to quit successfully. To further reduce smoking worldwide, the World Health Organization (WHO) aims to support 100 million smokers in quitting for good through the ‘Commit to Quit’ campaign launched on World No Tobacco Day.³ Greater global efforts are needed to build on the WHO’s goals and drive us more rapidly towards a tobacco endgame.

Despite global reductions in tobacco use,⁴ the introduction of electronic cigarettes and other newer tobacco products with flavourings is dramatically impacting tobacco use in youth in certain parts of the world. In Europe, rates of e-cigarette use among 13- to 15-year olds are highest in Poland (23.4%), Ukraine (18.4%), Latvia (18.0%), and Italy (17.5%).⁵ In the USA, where government regulation of electronic cigarettes is nascent, the rate of youth use of electronic cigarettes has increased significantly. In 2020, >3.6 million adolescents in the USA used electronic cigarettes, including 19.6% of young people in grades 10–12.⁶ Heated tobacco, nicotine pouch products, and other emerging tobacco products typically include sweet, minty, and other nontobacco characterizing flavours and pose risks to global health, particularly among the young.

With this joint opinion, the American Heart Association (AHA), World Heart Federation, European Society of Cardiology, and American College of Cardiology call for greater action on a global scale to end the tobacco epidemic once and for all. Governments must take more immediate action to implement the WHO’s MPOWER⁷ framework, which outlines six essential policy strategies proven to reduce tobacco use, as contained in the WHO Framework Convention on Tobacco Control. To help accelerate progress made through WHO’s ‘Commit to Quit’ campaign, countries must fund comprehensive tobacco prevention strategies that allow full implementation of the MPOWER framework. Furthermore, governments must effectively regulate electronic cigarettes and other emerging tobacco products to protect young people and improve public health. The figure provides a summation of the current situation and the need for action Figure 1.
Nicotine, tobacco use, and health

Nicotine and health
Although most tobacco-related morbidity and mortality is attributable to other chemicals, nicotine is the main addictive substance in tobacco products that keeps individuals using tobacco and continuing their risk for suffering tobacco-related harms. As such, the concept of nicotine addiction and its consequences, in terms of harmful tobacco product use, should be central to regulatory and policy approaches to reduce tobacco use.

Nicotine poses risks to the cardiovascular system, including causing an increase in blood pressure, heart rate, flow of blood to the heart, and a narrowing of the arteries. Nicotine may also contribute to the hardening of the arterial walls, which in turn can lead to a heart attack. Nicotine also impacts brain development and poses dangers to youth, pregnant women, and the developing fetus. Nicotine exposure during adolescence can cause addiction and harm the developing brain. During pregnancy, nicotine can cross the placenta and result in multiple adverse consequences, including sudden infant death syndrome.

A greater understanding of the impacts of nicotine on cardiovascular health, and nicotine delivery products on children and youth, is necessary to inform further treatment and regulatory approaches to nicotine. Towards that end, the AHA committed $17 million in early 2020 to fund research regarding the adverse health effects of nicotine and to identify more effective treatment interventions to help young people quit nicotine products.

Combustible cigarettes and health
The deleterious health consequences of cigarette smoking are very well established. Smoking combustible cigarettes negatively impacts nearly every organ of the body, and the life expectancy of cigarette smokers is roughly 10 years less than non-smokers. Globally, smoking and exposure to second-hand smoke are responsible for roughly 1 in 5 (21%) of all deaths attributed to coronary heart disease. Tobacco use also increases risk associated with emerging diseases; as a recent example, available evidence suggests cigarette smoking is associated with increased severity of disease and death in hospitalized patients with coronavirus disease 2019 (COVID-19). Because the use of combustible tobacco products is the leading cause of preventable mortality and morbidity, substantially reducing such use represents one of the most significant opportunities to improve global health.

Electronic cigarettes and health
Long-term epidemiological studies of the individual and public health impact of e-cigarettes are challenging because these products have evolved rapidly since their emergence in the mid-2000s. In its comprehensive review, the US National Academies of Science, Engineering, and Medicine stated there is ‘conclusive evidence that in addition to nicotine, most e-cigarette products contain and emit numerous potentially toxic substances’ and that potential exposure to these toxic substances is highly variable given the range of product characteristics and how e-cigarette devices are used. Compared with the use of combustible tobacco cigarettes, a very high-risk comparator, e-cigarette use likely poses less risk. However, there is growing evidence that e-cigarettes and their aerosol constituents, nicotine, vapourizing solvents, particulate matter, metals, and flavourings can have deleterious effects on the cardiovascular system, respiratory system, and brain.

Although the long-term health effects on adults are unclear, e-cigarette use among youth poses a clear threat to public health. In the USA, the dramatic increase in e-cigarette use among young people is unprecedented, and millions of young people who would never...
have used cigarettes or other tobacco products are using e-cigarettes. The introduction of high-nicotine delivery systems such as JUUL transformed the e-cigarette landscape and increased the addiction potential for young people. E-cigarette use is also associated with increased odds of smoking combustible cigarettes among adolescents who had no previous intention of smoking conventional cigarettes,\textsuperscript{18} belying assertions that e-cigarettes play a major role in reducing overall nicotine and tobacco use.

Evidence is limited regarding the efficacy of e-cigarettes as a smoking cessation aid.\textsuperscript{13} Many e-cigarette users also continue to smoke cigarettes, and dual use of e-cigarettes while continuing to smoke traditional cigarettes is not associated with higher rates of quitting.\textsuperscript{19} A 2020 Cochrane review found only moderate evidence that quit rates were higher among those randomly assigned to receive nicotine e-cigarettes compared with nicotine replacement therapy and among those randomly assigned to receive nicotine e-cigarettes compared with nonnicotine e-cigarettes;\textsuperscript{20} however, these findings were based on only a few large randomized clinical trials. More research is needed to understand the efficacy of e-cigarettes in promoting quitting relative to approved pharmacotherapies. Additional work is also required to assess the prevalence and impact of dual use, whether the use of newer tobacco products is more likely to lead to complete abstinence from combustible tobacco use, and whether these products and e-cigarettes have adverse health effects if they are continued long-term.

Novel tobacco products and health
Heated tobacco, nicotine pouch products, and other novel tobacco products loosely represent an emerging class of tobacco products being marketed by industry as reduced-exposure or modified-risk products. There is currently limited evidence regarding either the long-term individual health risks posed by these products or their potential public health impact. Heated tobacco products contain nicotine and other potentially harmful constituents, and the potential of reduced exposure does not mean they are harmless or inherently related to reduced risk. Nicotine pouch products are one of the fastest-growing segments of the retail tobacco market in the USA, and there are strong concerns regarding their accessibility to and use by youth. Governments should introduce and enforce strong systems for thorough premarket assessment of any novel products and prevent industry from making health claims about products that are not substantiated by rigorous research and not authorized through regulatory review. Tobacco control interventions, such as MPOWER, should be applied to all tobacco products.

The role of flavours
Although several countries, including the European Union, USA, and Canada, have restricted the sale of certain flavoured tobacco products, greater action must be taken to ensure flavoured tobacco products are not increasing tobacco-related disparities and promoting youth initiation. For instance, in Singapore, multiple menthol cigarette brands were introduced in the 1980s to appeal to young smokers, and in 2018, menthol cigarettes represented 48% of the overall market. In the Philippines, where menthol cigarette use is high, cigarettes with flavour capsules have become increasingly popular.\textsuperscript{2} Today, roughly half of all US youth who smoke cigarettes report using menthol cigarettes,\textsuperscript{23} and an estimated 86% of Black smokers and 46% of Hispanic smokers smoke menthol cigarettes compared with only 29% of White smokers. Countries should follow the lead of the European Union, which has prohibited the sale of menthol cigarettes through the EU Tobacco Products Directive. Newer tobacco products, including e-cigarettes, heated tobacco, and nicotine pouch products, are sold in a wide range of youth-appealing flavours. Greater global action must be taken to remove all youth-appealing and other nonto-bacco characterizing flavours from all tobacco products.

Opportunity for global impact
There is tremendous potential to equitably reduce cardiovascular disease by implementing population-based tobacco prevention and control strategies. Implementing the WHO MPOWER framework effectively reduces tobacco use among adults and youth.\textsuperscript{24} Raising the price of tobacco products, through excise taxes and other means, and youth-targeted countermarketing campaigns effectively reduce tobacco use among youth.\textsuperscript{25} With these evidence-based strategies available, the WHO is monitoring progress towards a global target of a 30% relative reduction in tobacco use prevalence by 2025. Similarly, the AHA is working towards an ambitious tobacco endgame goal of 5% or less tobacco use prevalence in the USA.\textsuperscript{26} Unfortunately, current rates of tobacco use suggest these goals will not be met without stronger policy development and implementation.

An estimated 780 million adult smokers worldwide want to quit,\textsuperscript{3} and the WHO’s ‘Commit to Quit’ campaign aims to support 100 million of them in quitting successfully. Greater efforts must be made to support adult smokers who want to quit through treatment interventions and through policy measures that create supportive environments for cessation.

Evidence is clear that e-cigarettes pose a significant global health threat through dramatic increases in youth tobacco and nicotine use. Many countries have banned the commercialization of e-cigarettes and heated tobacco products using the precautionary principle (i.e. that the introduction of a new product or process whose ultimate effects are unknown should be deferred until scientific evidence of its safety is available) as justification. The International Union Against Tuberculosis and Lung Disease has outlined a strong rationale for why low- and middle-income countries should ban the sale of all electronic nicotine delivery systems entirely.\textsuperscript{27} Globally, more effective regulation of online sales of e-cigarettes and e-liquids is needed to make e-cigarettes less accessible to youth. Actions must be taken quickly in countries where e-cigarettes are widely used if we are to reduce youth nicotine addiction and tobacco use while providing access to comprehensive, evidence-based cessation services as a safer alternative for adults who wish to quit smoking combustible cigarettes.

Addressing the challenge: the role of American Heart Association and its partners
The AHA, World Heart Federation, American College of Cardiology, and European Society of Cardiology are committed
to ending the global tobacco epidemic through advocacy for policies proven to reduce tobacco use and by encouraging bolder government actions to protect public health. Together and with other global partners, we continue to monitor and draw attention to tobacco industry practices that promote its addictive and deadly products. Recognizing the tremendous toll that combustible tobacco products have on global health, we call for stronger government actions that more rapidly reduce the use of combustible tobacco products. Towards this aim, we support lowering nicotine concentrations in all combustible tobacco products while ensuring the next generation is not addicted to new nicotine delivery products.

The MPOWER framework and decades of experience in tobacco control provide a road map to achieving the tobacco endgame. We are calling on governments to raise the price of tobacco products to levels that effectively promote adult cessation and substantially reduce youth initiation. Eliminating the sale of menthol cigarettes and other flavoured tobacco products is essential to eradicating the global tobacco epidemic, and governments should eliminate the sale of all tobacco products with characterizing flavours to substantially reduce youth initiation and address tobacco-related disparities. Governments should protect people from tobacco smoke by enacting comprehensive smoke-free policies, including combustible, heated tobacco, and electronic products, for all indoor public places. To the extent possible under existing legal frameworks, governments should establish and enforce comprehensive bans on tobacco industry advertising, promotions, and sponsorships. Effective pictorial health warnings should be included on all tobacco product packaging, and where possible under existing legal frameworks, plain/standardized tobacco product packaging should be used.

We will also advocate for additional and more robust research to identify additional strategies that help established tobacco users quit successfully, with a particular focus on youth. We expect the same vigour of research and regulation to be applied to all products claiming efficacy in helping adults quit. For instance, well-designed clinical trials of any products with cessation potential, such as e-cigarettes, must be conducted under and reviewed by relevant drug administration laws and agencies.

Finally, governments must take greater actions to restrict or prohibit the sale of tobacco products while ensuring established tobacco users have the support needed to quit successfully.

Conflict of interest: M.S.V.E. serves as an unpaid Officer of the American Heart Association. A.P. reports financial interest in GE. The other authors report no conflicts of interest.

References

1. US National Cancer Institute and World Health Organization. The Economics of Tobacco and Tobacco Control: National Cancer Institute Tobacco Control Monograph 21. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute and World Health Organization: 2016. NIH publication No. 16-CA-8209A.

2. Tobacco Fact Sheet. World Health Organization website. https://www.who.int/news-room/fact-sheets/detail/tobacco. Date accessed 1 December 2020.

3. World Health Organization. WHO launches year-long campaign to help 105 million people quit tobacco. News release. December 8, 2020. https://www.who.int/news-room/releases/2020/12/monitoring-future-survey-results-show-alarming-rise-in-teen-vaping. Date accessed 1 December 2020.

4. World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Use 2000-2025. 3rd ed. Geneva: World Health Organization; 2019.

5. World Health Organization. Summary Results of the Global Youth Tobacco Survey in Selected Countries of the WHO European Region. WHO Regional Office for Europe: 2020. https://www.euro.who.int/en/health-topics/disease-prevention/tobacco/publications/2020/summary-results-of-the-global-youth-tobacco-survey-in-selected-countries-of-the-who-european-region-2020. Date Accessed 2 December 2020.

6. Wang TW, Neff LJ, Park-Lee E, Ren C, Cullen KA, King BA. E-cigarette use among middle and high school students: United States, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1310–1312.

7. WHO Tobacco-Free Initiative: MPOWER. World Health Organization website. https://www.who.int/tobacco/mpower/en/. Date accessed 16 November 2020.

8. US Department of Health and Human Services, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. E- Cigarette Use among Youth and Young Adults: A Report of the Surgeon General—Executive Summary. Centers for Disease Control and Prevention; 2016.

9. American Heart Association. Nearly $17 million invested in research to fast-track studies on health impacts of e-cigarettes and nicotine on youth. News release. April 21, 2020. https://newsroom.heart.org/news/nearly-17-million-invested-in-research-to-fast-track-studies-on-health-impacts-of-e-cigarettes-and-nicotine-on-youth. Date accessed 16 November 2020.

10. US Department of Health and Human Services, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. The Consequences of Smoking: 50 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention; 2014.

11. Jha P, Ramasundarahettige C, Landman V, Rostron B, Thun M, Anderson RN, McAfee T, Peto R. 21st century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013;368:341–350. doi:10.1056/NEJMsa1211128

12. World Health Organization. Smoking and COVID-19: Science Brief, 30 June 2020. WHO/2019-nCoV/Sci_Brief/Smoking/2020.2.

13. National Academies of Science, Engineering, and Medicine. Public Health Consequences of E-Cigarettes. Washington, DC: National Academies Press; 2018; doi:10.17226/24952.

14. Buchanan ND, Grimmer JA, Tanwar V, Schwietzerman N, Mohler PJ, Wold LE. Cardiovascular risk of electronic cigarettes: a review of preclinical and clinical studies. Cardiovasc Res 2020;116:40–50. doi: 10.1093/cvr/cvz256

15. Gotts JE, Jordt SE, McConnell R, Tarran R. What are the respiratory effects of e -cigarettes? [published correction appears in BMJ 2019;367:j3980]. BMJ 2019;367:i2575. doi: 10.1136/bmj/i2575

16. Kuntic M, Oelze M, Steven S, Kröller-Schohn S, Panning S, Kalinovic S, Freis K, Vujacic-Mirska K, Bayo Jimenez MT, Kvardova M, Filipppo K, Al Zuabi A, Brückl V, Hahad O, Daub S, Varveri F, Gori T, Huesmann R, Hoffmann T, Schmidt FP, Keaney JF, Daiber A, Münztel T. Short-term e-cigarette vapour exposure causes vascular oxidative stress and dysfunction: evidence for a close connection to brain damage and a key role of the phagocytic NADPH oxidase (NOX-2). Eur Heart J 2020;41:2472–2483. doi: 10.1093/eurheartj/ehz772

17. Volkow N. Monitoring the future survey results show alarming rise in teen vaping. National Institutes of Health, National Institute on Drug Abuse website. December 17, 2018. https://www.drugabuse.gov/about-nida/noras-blog/2018/12/monitoring-future-survey-results-show-alarming-rise-in-teen-vaping. Date accessed 1 December 2020.

18. Owotomo O, Stritzel H, McCabe SE, Boyd CJ, Maslowski J. Smoking intention and progression from e-cigarette use to cigarette smoking. Pediatrics 2020;146:e2020002881.

19. Jackson SE, Shahab L, West R, Brown J. Associations between dual use of e-cigarettes and smoking cessation: a prospective study of smokers in England. Addiction 2020;115:2366–2376. doi: 10.1111/add.15226.

20. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Butler AR. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2020;1:CD010216.

21. van der Eijk Y, Lee JK, Ling P. How menthol is key to the tobacco industry’s strategy of recruiting and retaining young smokers in Singapore. J Adolesc Health 2019;64:347–354. doi: 10.1016/j.jadohealth.2019.05.015.

22. Brown J, Zhu M, Moram M, Hoe C, Frejas F, Cohen JE. “It has candy. You need to press on it”: young adults’ perceptions of flavoured cigarettes in the Philippines. Addict Behav 2020;103:106230.

23. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Butler AR. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2020;1:CD010216.

24. van der Eijk Y, Lee JK, Ling P. How mental is key to the tobacco industry’s strategy of recruiting and retaining young smokers in Singapore. J Adolesc Health 2019;64:347–354.

25. Ng P, Cheng KW, Chaloupka FJ, Shang C. The effect of MPOWER scores on cigarette smoking prevalence and consumption. Prev Med 2017;105:310–314.

26. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Preventing Tobacco Use among Youth and Young Adults: A Report of the Surgeon General. Centers for Disease Control and Prevention (US); 2012.

Joint opinion
26. Bhatnagar A, Whitsel LP, Blaha MJ, Huffman MD, Krishan-Sarin S, Maa J, Rigotti N, Robertson RM, Warner JJ. New and emerging tobacco products and the nicotine endgame: the role of robust regulation and comprehensive tobacco control and prevention; a presidential advisory from the American Heart Association. Circulation 2019;139:e937–e958.

27. The International Union against Tuberculosis and Lung Disease. Where Bans Are Best: Why LMICs Must Prohibit E-Cigarette and HTP Sales to Truly Tackle Tobacco: 2020 Updated Position Paper. The Union; 2020. https://theunion.org/technical-publications/union-position-paper-on-e-cigarettes-and-htp-sales-in-lmics. Date Accessed 2 December 2020.